ZYN002 - Cannabidiol Transdermal Gel clinical trials

Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

This study is looking at the long-term safety of a cannabidiol gel (ZYN002) for children and teenagers with Fragile X Syndrome. Participants previously took part in other ZYN002 studies. The gel is applied to the skin twice a day for at least a year.